Bolt Biotherapeutics, Inc. (BOLT) intrinsic value & 10-year financials
Bolt Biotherapeutics, Inc. (BOLT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 101.6% a year to $7.7M, with an average return on invested capital of -52.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $4.00
- Market cap
- $7.5M
- Revenue (FY2025)
- $7.7M
- Revenue growth (7-yr CAGR)
- 101.6%
- ROIC (10-yr avg)
- -52.7%
- Free cash flow (FY2025)
- -$39.9M
BOLT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $7.7M | -$33.4M | -$17.85 | -$39.9M | -469.3% | -66.9% |
| FY2024 | $7.7M | -$63.1M | -$1.65 | -$61.3M | -949.9% | -76.0% |
| FY2023 | $7.9M | -$69.2M | -$1.83 | -$69.7M | -967.4% | -50.5% |
| FY2022 | $5.7M | -$88.1M | -$2.36 | -$78.5M | -1576.6% | -42.3% |
| FY2021 | $1.3M | -$98.6M | -$2.97 | -$59.4M | -7364.1% | -129.3% |
| FY2020 | $231.0K | -$60.7M | — | -$50.6M | -21290.9% | 48.6% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Bolt Biotherapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Bolt Biotherapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -52.7% ROIC.
Bolt Biotherapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Bolt Biotherapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-592.90 per share.